Jeffery P Struewing
Overview
Explore the profile of Jeffery P Struewing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
2808
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Freedman A, Klabunde C, Wiant K, Enewold L, Gray S, Filipski K, et al.
JCO Precis Oncol
. 2022 Feb;
2.
PMID: 35135159
Purpose: There are no nationally representative data on oncologists' use of next-generation sequencing (NGS) testing in practice. The purpose of this study was to investigate how oncologists in the United...
2.
Goldman J, Chung W, Lee B, Chen C, Lu C, Hoetzenecker W, et al.
Eur J Clin Pharmacol
. 2019 Jun;
75(9):1331.
PMID: 31254013
The correct name of the 9th Author is David J. Margolis. The original article was corrected.
3.
Goldman J, Chung W, Lee B, Chen C, Lu C, Hoetzenecker W, et al.
Eur J Clin Pharmacol
. 2019 Mar;
75(8):1135-1141.
PMID: 30918988
Purpose: Establishment of causality between drug exposure and adverse drug reactions (ADR) is challenging even for serious ADRs such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Several causality assessment tools (CAT)...
4.
White K, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, et al.
J Allergy Clin Immunol Pract
. 2018 Jan;
6(1):38-69.
PMID: 29310768
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening, immunologically mediated, and usually drug-induced disease with a high burden to individuals, their families, and society with an annual incidence of 1...
5.
Mucci N, Moore H, Brigham L, Goldthwaite C, Little A, Lockhart N, et al.
Biopreserv Biobank
. 2014 May;
11(2):77-82.
PMID: 24845428
Normal human tissues, bodily fluids, and other biospecimens of known quality are essential for research to understand the development of cancer and other diseases and to develop new diagnostics and...
6.
McCarty C, Chisholm R, Chute C, Kullo I, Jarvik G, Larson E, et al.
BMC Med Genomics
. 2011 Jan;
4:13.
PMID: 21269473
Introduction: The eMERGE (electronic MEdical Records and GEnomics) Network is an NHGRI-supported consortium of five institutions to explore the utility of DNA repositories coupled to Electronic Medical Record (EMR) systems...
7.
Korde L, Mueller C, Loud J, Struewing J, Nichols K, Greene M, et al.
Breast Cancer Res Treat
. 2010 May;
125(1):169-73.
PMID: 20458532
This analysis addresses risk of breast cancer among women in BRCA-positive families who test negative for the family mutation. We compared the number of prospectively diagnosed breast cancers in 395...
8.
Mai P, Chatterjee N, Hartge P, Tucker M, Brody L, Struewing J, et al.
PLoS One
. 2009 Mar;
4(3):e4812.
PMID: 19277124
Background: Although the increase in risk of developing breast, ovarian, and prostate cancer in BRCA1 and BRCA2 mutation carriers has been studied extensively, its impact on mortality is not well...
9.
Udler M, Meyer K, Pooley K, Karlins E, Struewing J, Zhang J, et al.
Hum Mol Genet
. 2009 Feb;
18(9):1692-703.
PMID: 19223389
Genome-wide association studies have identified FGFR2 as a breast cancer (BC) susceptibility gene in populations of European and Asian descent, but a causative variant has not yet been conclusively identified....
10.
Sigurdson A, Bhatti P, Chang S, Rajaraman P, Doody M, Bowen L, et al.
Breast Cancer Res Treat
. 2009 Feb;
118(1):177-84.
PMID: 19214745
Ionizing radiation-associated breast cancer risk appears to be modified by timing of reproductive events such as age at radiation exposure, parity, age at first live birth, and age at menopause....